These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 17200688)

  • 1. Are heat shock proteins therapeutic target for Parkinson's disease?
    Luo GR; Chen S; Le WD
    Int J Biol Sci; 2006 Oct; 3(1):20-6. PubMed ID: 17200688
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protective role of heat shock proteins in Parkinson's disease.
    Aridon P; Geraci F; Turturici G; D'Amelio M; Savettieri G; Sconzo G
    Neurodegener Dis; 2011; 8(4):155-68. PubMed ID: 21212626
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential application of heat shock proteins as therapeutic targets in Parkinson's disease.
    Guo H; Yi J; Wang F; Lei T; Du H
    Neurochem Int; 2023 Jan; 162():105453. PubMed ID: 36402293
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heat shock proteins in neurodegenerative diseases: pathogenic roles and therapeutic implications.
    Adachi H; Katsuno M; Waza M; Minamiyama M; Tanaka F; Sobue G
    Int J Hyperthermia; 2009 Dec; 25(8):647-54. PubMed ID: 20021225
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heat shock proteins reduce alpha-synuclein aggregation induced by MPP+ in SK-N-SH cells.
    Fan GH; Zhou HY; Yang H; Chen SD
    FEBS Lett; 2006 May; 580(13):3091-8. PubMed ID: 16678164
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Translational Shift of HSP90 as a Novel Therapeutic Target from Cancer to Neurodegenerative Disorders: An Emerging Trend in the Cure of Alzheimer's and Parkinson's Diseases.
    Alam Q; Alam MZ; Sait KHW; Anfinan N; Noorwali AW; Kamal MA; Khan MSA; Haque A
    Curr Drug Metab; 2017; 18(9):868-876. PubMed ID: 28758577
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulating Stress Proteins in Response to Therapeutic Interventions for Parkinson's Disease.
    Silvestro S; Raffaele I; Mazzon E
    Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term heat shock proteins (HSPs) induction by carbenoxolone improves hallmark features of Parkinson's disease in a rotenone-based model.
    Thakur P; Nehru B
    Neuropharmacology; 2014 Apr; 79():190-200. PubMed ID: 24296154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ubiquitin-proteasome system and Parkinson's diseases.
    Betarbet R; Sherer TB; Greenamyre JT
    Exp Neurol; 2005 Feb; 191 Suppl 1():S17-27. PubMed ID: 15629758
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of iron in UPS impairment model of Parkinson's disease.
    Le W
    Parkinsonism Relat Disord; 2014 Jan; 20 Suppl 1():S158-61. PubMed ID: 24262171
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene expression profiling of sporadic Parkinson's disease substantia nigra pars compacta reveals impairment of ubiquitin-proteasome subunits, SKP1A, aldehyde dehydrogenase, and chaperone HSC-70.
    Mandel S; Grunblatt E; Riederer P; Amariglio N; Jacob-Hirsch J; Rechavi G; Youdim MB
    Ann N Y Acad Sci; 2005 Aug; 1053():356-75. PubMed ID: 16179542
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Parkinson's disease: oxidative stress and therapeutic approaches.
    Surendran S; Rajasankar S
    Neurol Sci; 2010 Oct; 31(5):531-40. PubMed ID: 20221655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protein folding and misfolding in the neurodegenerative disorders: a review.
    Bolshette NB; Thakur KK; Bidkar AP; Trandafir C; Kumar P; Gogoi R
    Rev Neurol (Paris); 2014 Mar; 170(3):151-61. PubMed ID: 24613386
    [TBL] [Abstract][Full Text] [Related]  

  • 14. UCH-L1 aggresome formation in response to proteasome impairment indicates a role in inclusion formation in Parkinson's disease.
    Ardley HC; Scott GB; Rose SA; Tan NG; Robinson PA
    J Neurochem; 2004 Jul; 90(2):379-91. PubMed ID: 15228595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Applying chaperones to protein-misfolding disorders: molecular chaperones against α-synuclein in Parkinson's disease.
    Chaari A; Hoarau-Véchot J; Ladjimi M
    Int J Biol Macromol; 2013 Sep; 60():196-205. PubMed ID: 23748003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heat Shock Proteins: Agents of Cancer Development and Therapeutic Targets in Anti-Cancer Therapy.
    Yun CW; Kim HJ; Lim JH; Lee SH
    Cells; 2019 Dec; 9(1):. PubMed ID: 31878360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulation of protein turnover by heat shock proteins.
    Bozaykut P; Ozer NK; Karademir B
    Free Radic Biol Med; 2014 Dec; 77():195-209. PubMed ID: 25236750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Neurodegenerative conformational disease and heat shock proteins].
    Kong XC; Bao XQ; Liu GT
    Yao Xue Xue Bao; 2010 Nov; 45(11):1333-8. PubMed ID: 21361031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular pathogenesis of Parkinson's disease.
    Gandhi S; Wood NW
    Hum Mol Genet; 2005 Sep; 14(18):2749-55. PubMed ID: 16126732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stress proteins in CNS inflammation.
    van Noort JM
    J Pathol; 2008 Jan; 214(2):267-75. PubMed ID: 18161755
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.